Skip to main content
Health innovation for the people

Health innovation policy for the people

Redesigning the enterprise Expanding democratic ownership

The US government has long played a central role in innovation, both through the patent system and by directly supporting research and development. In articulating innovation priorities and defining how to achieve them, policymakers have relied heavily on the expertise of scientists and market players. This has expanded the technical workforce, increased the numbers of scientific publications and patents, and produced macroeconomic growth. The benefits for the population are less clear: there is growing social and economic inequality and the needs of marginalized groups are invariably ignored.

This paper identifies four harms of this approach, specifically for health equity. It does not consider concerns of accessibility or affordability, defining these as health care, rather than innovation, problems. It limits the range of innovators, and also distorts innovation incentives. Finally, it tolerates harmful, and even biased, innovation. It concludes with recommendations for addressing these negative consequences: sponsoring much more interdisciplinary research, engaging marginalized communities as experts, and exploring nonmarket avenues for health innovation.

Download and read now:

More related work

Default Image

Healthcare as a public service: Redesigning U.S. healthcare with health and equity at the center

The Veterans Health Administration—the country’s only fully public, integrated healthcare system—has a lot to tell us about how a national healthcare service for the United States might operate.

read more
Default Image

The case for investing in employee ownership

For many years now, conventional solutions to income and wealth inequality—minimum wage, unions, progressive taxation, or guaranteed income—have failed to gain enough momentum to reverse the trend of greater and greater accumulation among the already well-off. What if we added a new approach

read more
Medicine Cost

Americans deserve publicly owned generic drugs

Bold policies could have saved America’s largest generic drug plant, but it’s never too late to start putting communities first.

read more